製品の概要

  • 製品名Anti-Msx2/Hox8 antibody
    Msx2/Hox8 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to Msx2/Hox8
  • アプリケーション適用あり: ICC/IF, WBmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Cow, Dog, Non Human Primates
  • 免疫原

    Synthetic peptide conjugated to KLH derived from within residues 1 - 100 of Human Msx2/Hox8.

    (Peptide available as ab86937.)

  • ポジティブ・コントロール
    • This antibody gave a positive signal in the following whole cell lysates: Saos 2; U2OS; JEG-3

製品の特性

関連製品

アプリケーション

Our Abpromise guarantee covers the use of ab69058 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ICC/IF Use a concentration of 1 µg/ml.
WB Use a concentration of 1 µg/ml. Detects a band of approximately 29 kDa (predicted molecular weight: 29 kDa).

ターゲット情報

  • 機能Acts as a transcriptional regulator in bone development. Represses the ALPL promoter activity and antogonizes the stimulatory effect of DLX5 on ALPL expression during osteoblast differentiation. Probable morphogenetic role. May play a role in limb-pattern formation. In osteoblasts, suppresses transcription driven by the osteocalcin FGF response element (OCFRE). Binds to the homeodomain-response element of the ALPL promoter.
  • 関連疾患Defects in MSX2 are the cause of parietal foramina 1 (PFM1) [MIM:168500]; also known as foramina parietalia permagna (FPP). PFM1 is an autosomal dominant disease characterized by oval defects of the parietal bones caused by deficient ossification around the parietal notch, which is normally obliterated during the fifth fetal month.
    Defects in MSX2 are the cause of parietal foramina with cleidocranial dysplasia (PFMCCD) [MIM:168550]; also known as cleidocranial dysplasia with parietal foramina. PFMCCD combines skull defects in the form of enlarged parietal foramina and deficient ossification of the clavicles.
    Defects in MSX2 are the cause of craniosynostosis type 2 (CRS2) [MIM:604757]; also known as craniosynostosis Boston-type (CSB). CRS2 is an autosomal dominant disorder characterized by the premature fusion of calvarial sutures. The craniosynostosis phenotype is either fronto-orbital recession, or frontal bossing, or turribrachycephaly, or cloverleaf skull. Associated features include severe headache, high incidence of visual problems (myopia or hyperopia), and short first metatarsals. Intelligence is normal.
  • 配列類似性Belongs to the Msh homeobox family.
    Contains 1 homeobox DNA-binding domain.
  • 細胞内局在Nucleus.
  • Information by UniProt
  • 参照データベース
  • 別名
    • CRS 2 antibody
    • CRS2 antibody
    • FPP antibody
    • Homeo box msh like 2 antibody
    • Homeobox protein Hox-8 antibody
    • Homeobox protein MSX 2 antibody
    • Homeobox protein MSX-2 antibody
    • Homeobox protein MSX2 antibody
    • Hox 8 antibody
    • Hox8 antibody
    • MSH antibody
    • Msh homeo box 2 antibody
    • Msh homeo box homolog antibody
    • Msh homeo box homolog 2 antibody
    • Msh homeobox 2 antibody
    • Msh homeobox homolog 2 antibody
    • Msx 2 antibody
    • MSX2 antibody
    • MSX2_HUMAN antibody
    • Parietal foramina 1 antibody
    • PFM 1 antibody
    • PFM antibody
    • PFM1 antibody
    see all

Anti-Msx2/Hox8 antibody 画像

  • All lanes : Anti-Msx2/Hox8 antibody (ab69058) at 1 µg/ml

    Lane 1 : Saos 2 (Human epithelial-like osteosarcoma cell line) Whole Cell Lysate
    Lane 2 : U2OS (Human osteosarcoma cell line) Whole Cell Lysate
    Lane 3 : JEG-3 (Human placental choriocarcinoma cell line) Whole Cell Lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 29 kDa
    Observed band size : 29 kDa
    Additional bands at : 48 kDa,55 kDa. We are unsure as to the identity of these extra bands.
  • ICC/IF image of ab69058 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab69058, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 100% methanol fixed (5 min) Hek293, HepG2 and MCF7 cells at 1µg/ml, and in 4% PFA fixed (10 min) HeLa, Hek293, HepG2 and MCF7 cells at 1µg/ml.

Anti-Msx2/Hox8 antibody (ab69058) 使用論文

ab69058 has not yet been referenced specifically in any publications.

Product Wall

Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Mouse Tissue lysate - whole (U2OS Ms Kidney Ms Brain Ms Spleen)
Specification U2OS Ms Kidney Ms Brain Ms Spleen
Gel Running Conditions Reduced Denaturing (Pierce precise protein gel 8-16%)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 21°C
Username

Mr. Antibody Solutions

Verified customer

投稿 Jun 01 2010

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Heart)
Specification Heart
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Dako Target Retrieval Solution
Permeabilization No
Blocking step 5 minutes of peroxidase block then 10 minutes of protein block. These are ready-to-use reagents purchased from Dako as blocking agent for 15 minute(s) · Concentration: 100% · Temperature: 20°C
Username

Mr. Antibody Solutions

Verified customer

投稿 Apr 27 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"